My thought are.
No trifecta but a very good Double.
1/Response rate was Higher with sirt by 7.4%
2/Both the side effect profile and QUALITY OF LIFE was much better over time in the sirt group.
3/ if patient Re not tolerant or have contraindications for Sorafenib therapy there are currently no standard of care .
Paragraph 2 an 3 is the key for me.
Yes i get it the primary end point did not show an overall survival superiority
I the end quality of life is far more important.
Glta
SRX Price at posting:
$17.00 Sentiment: Buy Disclosure: Held
